Effect of EARLY administration of DEXamethasone in patients with COVID-19 pneumonia without acute hypoxemic respiratory failure and risk of development of acute respiratory distress syndrome (EARLY-DEX COVID-19) : study protocol for a randomized controlled trial
© 2022. The Author(s)..
BACKGROUND: Corticosteroids are one of the few drugs that have shown a reduction in mortality in coronavirus disease 2019 (COVID-19). In the RECOVERY trial, the use of dexamethasone reduced 28-day mortality compared to standard care in hospitalized patients with suspected or confirmed COVID-19 requiring supplemental oxygen or invasive mechanical ventilation. Evidence has shown that 30% of COVID-19 patients with mild symptoms at presentation will progress to acute respiratory distress syndrome (ARDS), particularly patients in whom laboratory inflammatory biomarkers associated with COVID-19 disease progression are detected. We postulated that dexamethasone treatment in hospitalized patients with COVID-19 pneumonia without additional oxygen requirements and at risk of progressing to severe disease might lead to a decrease in the development of ARDS and thereby reduce death.
METHODS/DESIGN: This is a multicenter, randomized, controlled, parallel, open-label trial testing dexamethasone in 252 adult patients with COVID-19 pneumonia who do not require supplementary oxygen on admission but are at risk factors for the development of ARDS. Risk for the development of ARDS is defined as levels of lactate dehydrogenase > 245 U/L, C-reactive protein > 100 mg/L, and lymphocyte count of < 0.80 × 109/L. Eligible patients will be randomly assigned to receive either dexamethasone or standard of care. Patients in the dexamethasone group will receive a dose of 6 mg once daily during 7 days. The primary outcome is a composite of the development of moderate or more severe ARDS and all-cause mortality during the 30-day period following enrolment.
DISCUSSION: If our hypothesis is correct, the results of this study will provide additional insights into the management and progression of this specific subpopulation of patients with COVID-19 pneumonia without additional oxygen requirements and at risk of progressing to severe disease.
TRIAL REGISTRATION: ClinicalTrials.gov NCT04836780. Registered on 8 April 2021 as EARLY-DEX COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Trials - 23(2022), 1 vom: 15. Sept., Seite 784 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Franco-Moreno, Anabel [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.09.2022 Date Revised 07.12.2022 published: Electronic ClinicalTrials.gov: NCT04836780 Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13063-022-06722-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346265800 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346265800 | ||
| 003 | DE-627 | ||
| 005 | 20231226031019.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13063-022-06722-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1154.xml |
| 035 | |a (DE-627)NLM346265800 | ||
| 035 | |a (NLM)36109825 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Franco-Moreno, Anabel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of EARLY administration of DEXamethasone in patients with COVID-19 pneumonia without acute hypoxemic respiratory failure and risk of development of acute respiratory distress syndrome (EARLY-DEX COVID-19) |b study protocol for a randomized controlled trial |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.09.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04836780 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a BACKGROUND: Corticosteroids are one of the few drugs that have shown a reduction in mortality in coronavirus disease 2019 (COVID-19). In the RECOVERY trial, the use of dexamethasone reduced 28-day mortality compared to standard care in hospitalized patients with suspected or confirmed COVID-19 requiring supplemental oxygen or invasive mechanical ventilation. Evidence has shown that 30% of COVID-19 patients with mild symptoms at presentation will progress to acute respiratory distress syndrome (ARDS), particularly patients in whom laboratory inflammatory biomarkers associated with COVID-19 disease progression are detected. We postulated that dexamethasone treatment in hospitalized patients with COVID-19 pneumonia without additional oxygen requirements and at risk of progressing to severe disease might lead to a decrease in the development of ARDS and thereby reduce death | ||
| 520 | |a METHODS/DESIGN: This is a multicenter, randomized, controlled, parallel, open-label trial testing dexamethasone in 252 adult patients with COVID-19 pneumonia who do not require supplementary oxygen on admission but are at risk factors for the development of ARDS. Risk for the development of ARDS is defined as levels of lactate dehydrogenase > 245 U/L, C-reactive protein > 100 mg/L, and lymphocyte count of < 0.80 × 109/L. Eligible patients will be randomly assigned to receive either dexamethasone or standard of care. Patients in the dexamethasone group will receive a dose of 6 mg once daily during 7 days. The primary outcome is a composite of the development of moderate or more severe ARDS and all-cause mortality during the 30-day period following enrolment | ||
| 520 | |a DISCUSSION: If our hypothesis is correct, the results of this study will provide additional insights into the management and progression of this specific subpopulation of patients with COVID-19 pneumonia without additional oxygen requirements and at risk of progressing to severe disease | ||
| 520 | |a TRIAL REGISTRATION: ClinicalTrials.gov NCT04836780. Registered on 8 April 2021 as EARLY-DEX COVID-19 | ||
| 650 | 4 | |a Clinical Trial Protocol | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adult respiratory distress syndrome | |
| 650 | 4 | |a COVID-19 pneumonia | |
| 650 | 4 | |a Corticosteroids | |
| 650 | 4 | |a Dexamethasone | |
| 650 | 4 | |a Inflammatory biological markers | |
| 650 | 4 | |a Laboratory markers | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Randomized controlled trial | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 650 | 7 | |a Lactate Dehydrogenases |2 NLM | |
| 650 | 7 | |a EC 1.1.- |2 NLM | |
| 650 | 7 | |a Oxygen |2 NLM | |
| 650 | 7 | |a S88TT14065 |2 NLM | |
| 700 | 1 | |a Acedo-Gutiérrez, María Soledad |e verfasserin |4 aut | |
| 700 | 1 | |a Martín, Nicolás Labrador-San |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Blanco, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Olleros, Celia |e verfasserin |4 aut | |
| 700 | 1 | |a Ibáñez-Estéllez, Fátima |e verfasserin |4 aut | |
| 700 | 1 | |a Suárez-Simón, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Balado-Rico, Mateo |e verfasserin |4 aut | |
| 700 | 1 | |a Romero-Paternina, Ana Rocío |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso-Menchén, David |e verfasserin |4 aut | |
| 700 | 1 | |a Escolano-Fernández, Belén |e verfasserin |4 aut | |
| 700 | 1 | |a Piniella-Ruiz, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso-Monge, Ester |e verfasserin |4 aut | |
| 700 | 1 | |a Notario-Leo, Helena |e verfasserin |4 aut | |
| 700 | 1 | |a Bibiano-Guillén, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Peña-Lillo, Gabriela |e verfasserin |4 aut | |
| 700 | 1 | |a Antiqueira-Pérez, Armando |e verfasserin |4 aut | |
| 700 | 1 | |a Romero-Pareja, Rodolfo |e verfasserin |4 aut | |
| 700 | 1 | |a Cabello-Clotet, Noemí |e verfasserin |4 aut | |
| 700 | 1 | |a Estrada-Pérez, Vicente |e verfasserin |4 aut | |
| 700 | 1 | |a Troya-García, Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a de Carranza-López, María |e verfasserin |4 aut | |
| 700 | 1 | |a Escobar-Rodríguez, Ismael |e verfasserin |4 aut | |
| 700 | 1 | |a Vallejo-Maroto, Nacho |e verfasserin |4 aut | |
| 700 | 1 | |a Torres-Macho, Juan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Trials |d 2006 |g 23(2022), 1 vom: 15. Sept., Seite 784 |w (DE-627)NLM161320430 |x 1745-6215 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:1 |g day:15 |g month:09 |g pages:784 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13063-022-06722-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2022 |e 1 |b 15 |c 09 |h 784 | ||